Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 562

1.

PSA Doubling Time and Absolute PSA Predict Metastasis-free Survival in Men With Biochemically Recurrent Prostate Cancer After Radical Prostatectomy.

Markowski MC, Chen Y, Feng Z, Cullen J, Trock BJ, Suzman D, Antonarakis ES, Paller CJ, Rosner I, Han M, Walsh PC, Partin AW, Eisenberger M.

Clin Genitourin Cancer. 2019 Aug 21. pii: S1558-7673(19)30251-4. doi: 10.1016/j.clgc.2019.08.002. [Epub ahead of print]

PMID:
31530439
2.

In Reply.

Brennen WN, Schweizer MT, Wang H, Bivalacqua TJ, Partin AW, Lim SJ, Chapman C, Abdallah R, Levy O, Bhowmick NA, Karp JM, De Marzo A, Isaacs JT, Denmeade SR.

Stem Cells Transl Med. 2019 Jul;8(7):739-740. doi: 10.1002/sctm.19-0068. Epub 2019 Mar 29. No abstract available.

3.

A Phase I Study to Assess the Safety and Cancer-Homing Ability of Allogeneic Bone Marrow-Derived Mesenchymal Stem Cells in Men with Localized Prostate Cancer.

Schweizer MT, Wang H, Bivalacqua TJ, Partin AW, Lim SJ, Chapman C, Abdallah R, Levy O, Bhowmick NA, Karp JM, De Marzo A, Isaacs JT, Brennen WN, Denmeade SR.

Stem Cells Transl Med. 2019 May;8(5):441-449. doi: 10.1002/sctm.18-0230. Epub 2019 Feb 8.

4.

Evaluating the impact of length of time from diagnosis to surgery in patients with unfavourable intermediate-risk to very-high-risk clinically localised prostate cancer.

Gupta N, Bivalacqua TJ, Han M, Gorin MA, Challacombe BJ, Partin AW, Mamawala MK.

BJU Int. 2019 Aug;124(2):268-274. doi: 10.1111/bju.14659. Epub 2019 Jan 27.

PMID:
30570825
5.

Best of the 2018 AUA Annual Meeting.

Schwen ZR, Partin AW; James Buchanan Brady Urological.

Rev Urol. 2018;20(2):98-100. doi: 10.3909/riu0806. No abstract available.

6.

Subtyping the Risk of Intermediate Risk Prostate Cancer for Active Surveillance Based on Adverse Pathology at Radical Prostatectomy.

Patel HD, Gupta M, Tosoian JJ, Carter HB, Partin AW, Epstein JI.

J Urol. 2018 Nov;200(5):1068-1074. doi: 10.1016/j.juro.2018.04.058. Epub 2018 Apr 17.

PMID:
29673946
7.

Adjuvant radiation with androgen-deprivation therapy for men with lymph node metastases after radical prostatectomy: identifying men who benefit.

Gupta M, Patel HD, Schwen ZR, Tran PT, Partin AW.

BJU Int. 2019 Feb;123(2):252-260. doi: 10.1111/bju.14241. Epub 2018 May 1.

PMID:
29626845
8.

Diagnosing small bowel carcinoid tumor in a patient with oligometastatic prostate cancer imaged with PSMA-Targeted [18F]DCFPyL PET/CT: Value of the PSMA-RADS-3D Designation.

Shenderov E, Gorin MA, Kim S, Johnson PT, Allaf ME, Partin AW, Pomper MG, Antonarakis ES, Pienta KJ, Rowe SP.

Urol Case Rep. 2017 Dec 19;17:22-25. doi: 10.1016/j.eucr.2017.12.011. eCollection 2018 Mar.

9.

Initial Experience Performing In-office Ultrasound-guided Transperineal Prostate Biopsy Under Local Anesthesia Using the PrecisionPoint Transperineal Access System.

Meyer AR, Joice GA, Schwen ZR, Partin AW, Allaf ME, Gorin MA.

Urology. 2018 May;115:8-13. doi: 10.1016/j.urology.2018.01.021. Epub 2018 Feb 1.

PMID:
29409845
10.

Best of the 2017 AUA Annual Meeting: Highlights From the 2017 American Urological Association Annual Meeting, May 12-16, 2017, Boston, MA.

Arcila-Ruiz MJ, Assimos DG, Brucker BM, Chancellor MB, Druskin SC, Curtis Nickel J, Partin AW, Shapiro E.

Rev Urol. 2017;19(3):169-179. doi: 10.3909/riu0763. Review. No abstract available.

11.

Pharmacodynamic and pharmacokinetic neoadjuvant study of hedgehog pathway inhibitor Sonidegib (LDE-225) in men with high-risk localized prostate cancer undergoing prostatectomy.

Ross AE, Hughes RM, Glavaris S, Ghabili K, He P, Anders NM, Harb R, Tosoian JJ, Marchionni L, Schaeffer EM, Partin AW, Allaf ME, Bivalacqua TJ, Chapman C, O'Neal T, DeMarzo AM, Hurley PJ, Rudek MA, Antonarakis ES.

Oncotarget. 2017 Oct 26;8(61):104182-104192. doi: 10.18632/oncotarget.22115. eCollection 2017 Nov 28.

12.

Combining Prostate Health Index density, magnetic resonance imaging and prior negative biopsy status to improve the detection of clinically significant prostate cancer.

Druskin SC, Tosoian JJ, Young A, Collica S, Srivastava A, Ghabili K, Macura KJ, Carter HB, Partin AW, Sokoll LJ, Ross AE, Pavlovich CP.

BJU Int. 2018 Apr;121(4):619-626. doi: 10.1111/bju.14098. Epub 2018 Jan 9.

13.

Profiling the Urinary Microbiome in Men with Positive versus Negative Biopsies for Prostate Cancer.

Shrestha E, White JR, Yu SH, Kulac I, Ertunc O, De Marzo AM, Yegnasubramanian S, Mangold LA, Partin AW, Sfanos KS.

J Urol. 2018 Jan;199(1):161-171. doi: 10.1016/j.juro.2017.08.001. Epub 2017 Aug 7.

14.

Risk factors for metastatic prostate cancer: A sentinel event case series.

Paller CJ, Cole AP, Partin AW, Carducci MA, Kanarek NF.

Prostate. 2017 May;77(13):1366-1372. doi: 10.1002/pros.23396. Epub 2017 Aug 8.

15.

Prostate Specific Membrane Antigen Targeted 18F-DCFPyL Positron Emission Tomography/Computerized Tomography for the Preoperative Staging of High Risk Prostate Cancer: Results of a Prospective, Phase II, Single Center Study.

Gorin MA, Rowe SP, Patel HD, Vidal I, Mana-Ay M, Javadi MS, Solnes LB, Ross AE, Schaeffer EM, Bivalacqua TJ, Partin AW, Pienta KJ, Szabo Z, De Marzo AM, Pomper MG, Allaf ME.

J Urol. 2018 Jan;199(1):126-132. doi: 10.1016/j.juro.2017.07.070. Epub 2017 Jul 20.

16.

Patterns of Pelvic Lymph Node Dissection at the Time of Radical Prostatectomy for Low-risk Men.

Chalfin HJ, Feng Z, Trock BJ, Partin AW.

Urology. 2017 Jun;104:143-149. doi: 10.1016/j.urology.2017.01.037. Epub 2017 Feb 21.

PMID:
28232176
17.

Use of the Prostate Health Index for detection of prostate cancer: results from a large academic practice.

Tosoian JJ, Druskin SC, Andreas D, Mullane P, Chappidi M, Joo S, Ghabili K, Agostino J, Macura KJ, Carter HB, Schaeffer EM, Partin AW, Sokoll LJ, Ross AE.

Prostate Cancer Prostatic Dis. 2017 Jun;20(2):228-233. doi: 10.1038/pcan.2016.72. Epub 2017 Jan 24.

18.

CLINICAL EVALUATION OF AN EPIGENETIC ASSAY TO PREDICT MISSED CANCER IN PROSTATE BIOPSY SPECIMENS.

Partin AW, VAN Criekinge W, Trock BJ, Epstein JI, VAN Neste L.

Trans Am Clin Climatol Assoc. 2016;127:313-327.

19.

Prostate Health Index density improves detection of clinically significant prostate cancer.

Tosoian JJ, Druskin SC, Andreas D, Mullane P, Chappidi M, Joo S, Ghabili K, Mamawala M, Agostino J, Carter HB, Partin AW, Sokoll LJ, Ross AE.

BJU Int. 2017 Dec;120(6):793-798. doi: 10.1111/bju.13762. Epub 2017 Feb 6.

20.

Where it all Began.

Partin AW.

J Urol. 2017 Feb;197(2S):S153. doi: 10.1016/j.juro.2016.10.087. Epub 2016 Dec 20. No abstract available.

PMID:
28010965

Supplemental Content

Loading ...
Support Center